The company will collaborate with the Scripps Research Institute and the Doylestown, Pa.-based Hepatitis B Foundation on the project, which will be aimed toward the eventual development of a therapeutic for Hepatits B.
Nucleonics uses expressed interfering RNA, or eiRNA, for its gene silencing techniques.